Substituted Alkynylene Compounds Targeting EGFR and BCR Pathways
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, are limited and often come with significant side effects, necessitating the development of new anti-cancer agents that act through different mechanisms and pathways.
Innovation Solution
Development of novel substituted alkynylene derivatives and their pharmaceutical compositions, which can be used as anti-cancer agents, targeting various types of cancer, including lymphomas and leukemias, by inhibiting specific growth-promoting pathways such as EGFR signaling and BCR pathway components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat cancer, then cancer cell growth is inhibited, but significant side effects occur and treatment options are limited
Solution Approach 1:
The patent applies parameter changes by developing novel substituted alkynylene compounds with modified chemical structures (formula I) that differ from conventional chemotherapy agents. These structural parameter changes enable the compounds to inhibit cancer cell growth through different mechanisms, specifically targeting growth-promoting pathways while reducing the harmful side effects associated with traditional chemotherapy
Solution Approach 2:
The invention employs composite materials by creating complex substituted alkynylene compounds that combine multiple functional groups and structural elements (aryl, heteroaryl, cycloalkyl, heterocycloalkyl groups with various substituents). This composite molecular structure allows for targeted inhibition of cancer pathways while minimizing off-target effects that cause side effects
2Adaptability or versatility
If new anti-cancer agents are developed to act through different mechanisms, then treatment options are expanded and side effects are reduced, but the complexity of drug development increases
Solution Approach 1:
The patent applies segmentation by dividing the complex drug development process into systematic stages: identifying target pathways (EGFR signaling, BCR pathway), designing specific molecular structures (formula I with defined substituents A, B, R1-R4, X, Y), synthesizing compounds, and evaluating anticancer activity. This segmented approach manages development complexity while expanding treatment options through mechanism-based classification
Data Source
AI summary
The present invention relates to substituted alkynylene compounds represented by the compounds of formula (I), pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the therapeutic uses of the compounds of formula (I) as anti-cancer agents.



